ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces an update on P140 partnership discussions. In the Corporate Update notification of 23 October 2025, ImmuPharma advised that it had started to engage with a number of potential partners on P140, and that the Company’s stated objective was to complete a deal by the…

TR-1: Standard form for notification of major holdings from Lanstead To download form Click here

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO will be attending the forthcoming Bio-Europe Conference in Vienna, from 3-5 November 2025. BIO-Europe Vienna 2025, is the 31st annual premier biopharma partnering event. It brings together over 5,700 life science…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the launch of its new corporate website, marking another step in the Company’s scientific and corporate evolution and placing its proprietary P140 autoimmune platform at the forefront of its strategy. Website Showcase | P140 Platform – Scientific Advancement and Mechanism of…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the appointment of Ketan Patel to the Board, as an independent Non-Executive Director. The appointment is with immediate effect. Ketan is an experienced investment professional and brings extensive expertise in financial markets with a focus in the UK healthcare and life science sectors. He has been a long-term…

TR-1: Standard form for notification of major holdings from Luca & Associates AG To download form Click here

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that the Company has received notice of exercise of 500,000 warrants over New Ordinary Shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £25,000. New Ordinary Shares and Admission The New Ordinary Shares have been…

ImmuPharma plc (LSE : IMM), the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announces that the Company has received notice of exercise of 2,500,000 warrants over New Ordinary Shares of 1p each (“Ordinary Shares”) at an exercise price of 5p per share, for a consideration of £125,000. The New Ordinary Shares have been allotted today and…

ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announces key appointments, in conjunction with the filing of a groundbreaking new patent application for its lead asset P140, separately announced today. Recognising the significance of this major step forward, Dr Sébastien Goudreau has been promoted into the position of Chief…

ImmuPharma PLC (LSE: IMM), a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, today announces the filing of a groundbreaking new patent application for its lead asset P140, the world’s first “Immunormalizer.” The patent application which provides the potential for 20 years of commercial exclusivity, discloses a novel diagnostic test and precision treatment approach,…